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Abstract 
Pro-inflammatory cytokine-induced activation of nuclear factor, NF-κB plays an 
important role in leukocyte adhesion to, and subsequent migration across, brain 
endothelial cells (BECs), which is crucial for the development of neuroinflammatory 
disorders such as multiple sclerosis (MS). In contrast, microRNA-146a (miR-146a) 
has emerged as anti-inflammatory molecule by inhibiting NF-κB activity in various 
cell types, but its effect in BECs during neuroinflammation remains to be evaluated. 
Here, we show that miR-146a was up-regulated in microvessels of MS active lesions 
and the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE). 
In vitro, TNFα and IFNγ treatment of human cerebral microvascular endothelial cells 
(hCMEC/D3) led to up-regulation of miR-146a. Brain endothelial over-expression of 
miR-146a diminished, whereas knock-down of miR-146a augmented, cytokine-
stimulated adhesion of T cells to hCMEC/D3 cells, nuclear translocation of NF-κB 
and expression of adhesion molecules in hCMEC/D3 cells. Furthermore, brain 
endothelial miR-146a modulates NF-κB activity upon cytokine activation through 
targeting two novel signaling transducers, RhoA and nuclear factor of activated T 
cells 5 (NFAT5), as well as molecules previously identified, IL-1 receptor-associated 
kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6). We propose brain 
endothelial miR-146a as an endogenous NF-κB inhibitor in BECs associated with 
decreased leukocyte adhesion during neuroinflammation. 
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Introduction 
In neuroinflammation such as multiple sclerosis (MS), the blood brain barrier (BBB) 
becomes compromised with intensive migration of leukocytes into the central nervous 
system (CNS), contributing to disease pathogenesis.1 To migrate into the CNS, 
leukocytes follow a finely regulated sequence of events starting from tethering and 
rolling along the vessel, then firmly adhering to and emigrating out of the vasculature. 
Firm adhesion is triggered by chemokines and mediated by interactions between 
integrins on leukocytes and adhesion molecules on brain endothelial cells (BECs).2  
      Overwhelming evidence highlights that the nuclear factor, NF-κB, drives 
transcription of cell adhesion molecules, chemokines and pro-inflammatory 
cytokines.3 The NF-κB complex consists of a family of dimeric transcription factors 
comprising RelA (p65), RelB, c-Rel, p50 and p52. The classical pathway involves 
p50/p65 heterodimers complexed to IκB in unstimulated cells. Upon stimulation, 
IKKβ mediates the phosphorylation-induced ubiquitination of IκB which frees 
p50/p65 to translocate to the nucleus to initiate gene transcription.3 NF-κB also 
coordinates with other signaling pathways such as RhoA and transforming growth 
factor-β to modulate the inflammatory response.4,5 NF-κB has been proposed as a 
therapeutic target for the treatment of MS,3 thereby indicating endogenous inhibitors 
of NF-κB as potential novel therapies. 
      MicroRNAs (miRNAs) are endogenous non-coding RNAs approximately 22 
nucleotides long that pair to the 3’-untranslated region of messenger RNAs and 
incorporate them into RNA-induced silencing complexes to repress gene expression. 
Accumulating evidence implicates certain miRNAs in the pathogenesis of MS and 
experimental autoimmune encephalomyelitis (EAE): miR-155 contributes to the 
pathogenesis of EAE by modulating T cell differentiation and promoting endothelial 
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barrier dysfunction,6,7 whereas brain endothelial miR-125a-5p tightens BBB and 
prevents leukocyte migration during inflammation.8  
      NF-κB not only initiates the transcription of protein-encoding genes but also 
drives the precursors to miRNAs which act as feedback modulators of NF-κB.9 
Among them, miR-146a is a NF-κB-dependent gene and down-regulates NF-κB 
activities by repressing two signal transducers in human monocytes: TNF receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1).10 
Several studies suggest miR-146a as a molecular brake on inflammation, myeloid cell 
proliferation, and oncogenic transformation.11 The anti-inflammatory role of miR-
146a has been demonstrated in several cell types including monocytes,10 T cells,12 
astrocytes,13 human umbilical vein endothelial cells (HUVECs),14 and human 
BECs. 15 However, its function in BECs remains to be elucidated. Here we show that 
miR-146a is up-regulated in cytokine-activated BECs and decreases leukocyte 
adhesion by inhibiting NF-κB through repressing not only TRAF6 and IRAK1 but 
also RhoA and nuclear factor of activated T cells 5 (NFAT5).  
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Materials and Methods  
Human brain tissue and primary human T cells 
     Human brain tissues of MS patients (4 female and 2 male, 34 ~ 88 years old) and 
control patients (6 male, 35 ~ 84 years old) without neurological diseases were 
obtained from The UK Multiple Sclerosis Tissue Bank (Imperial College London, 
London, UK) according to local human ethical guidelines (For clinical information 
and pathological characterization of MS and control patients please see ref. 7). 
Primary human T cells were obtained from three healthy donors at VU University 
Medical Center, Amsterdam, The Netherlands, following the Netherlands human 
ethical guidelines.16 Briefly, human CD4+ and CD8+ T cells were purified from 
peripheral blood mononuclear cells using MACS® magnetic cell sorting kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. CD4+ and CD8+ T cell purity 
was >96 % as assessed by flow cytometry performed (FACSCalibur™) using 
CELQuestTM software (BD Biosciences).  
 
Cell lines 
     The immortalized human brain microvascular endothelial cell line (hCMEC/D3) 
was cultured on collagen-coated culture flasks or multi-well plates in EGM-2 MV 
medium supplemented with 2.5% foetal bovine serum (FBS) and growth factors 
(Lonza, Slough Wokingham, UK).7 The Jurkat T lymphocyte cell line was a kind gift 
from Dr V Male (Cambridge University, UK) and cultured in suspension in 
RPMI1640 (Life Technologies Ltd, Paisley, UK) with 10% FBS. 
 
Induction of experimental autoimmune encephalomyelitis (EAE) 
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     Adult female and male (10 – 12 weeks) Biozzi ABH mice were purchased from 
Harlan UK Ltd (Bicester, UK). Animals were grouped randomly and maintained on a 
12 h: 12 h light: dark cycle and received food and water ad libitum. All procedures 
were approved following ethical review processes in accordance with the Animals 
(Scientific Procedures) Act 1986 of the UK government. EAE was induced in Biozzi 
ABH mice with freeze-dried mouse spinal cord homogenate emulsified with complete 
Freunds adjuvant supplemented as previously described.7 Animals were monitored 
daily to assess the development of relapsing–remitting paralysis and scored as follows: 
0 = normal; 1 = limp tail; 2 = impaired righting reflex; 3 = hind-limb paresis; 4 = 
complete hind-limb paralysis and 5 = moribund/death. Two (2/44) animals scored 5 
were excluded from the experiments. The EAE status was based on paralytic clinical 
disease and weight loss/gain as follows: onset of signs: clinical score 1, with weight 
loss sampled on day 15 post induction; acute-phase paralysis (APP): clinical score 
3.5– 4, with weight loss by day 17; recovery: clinical score 3.5–1, with weight gain by 
day 20; remission one: clinical score 0.5, with weight gain by day 28 after induction. 
Reporting elements concerning experimental design of EAE experiments relating to 
the ARRIVE guidelines have been described previously.7 Data collection and analysis 
were performed by researchers blinded to the experimental groups.   
 
Laser capture microdissection and isolation of microvessels 
     Laser capture microdissection (LCM) of MS brain microvessels was used to 
collect enriched brain endothelium RNA as previously described.7 Approximately 200 
blood vessels were isolated from each case using PixCell II laser capture 
microdissection system (Arcturus BioScience, Mountain View, CA, USA) and LCM-
caps (Applied Biosystems, Warrington, UK). For mouse spinal cords, microvessels 
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were isolated as previously described.7 Briefly, EAE or normal ABH mice were 
perfused with 0.5% bovine serum albumin (BSA) in Hank’s balanced solution to rinse 
out the blood, then the spinal cords were flushed out of vertebral columns. For each 
replicate, spinal cords of 3 mice in the same group were pooled together to get 
sufficient amount of RNA and counted as one (total animals used, 9 mice per group), 
digested with collagenase and dispase (1mg/ml) at 37oC for 1 h, and, finally, 
homogenized and centrifuged through 25% BSA. The pellet of microvessels 
underwent a second digestion for 30 min and microvessel fragments were purified and 
separated from single contaminating cells by passing through a 70 μm size mesh filter. 
Enrichment of endothelium within the microvessel fraction was examined by 
quantitative RT-PCR for endothelial markers (claudin-5, PECAM-1), astrocyte 
marker GFAP and leukocyte marker CD45, as previously described.7,8 
 
RNA extraction and quantitative RT-PCR 
     Total RNA of hCMEC/D3 cells and microvessels isolated from human brain or 
mouse spinal cords were extracted using TRIzol reagent (Life Technologies Ltd, 
Paisley, UK). For each sample, 10 ng of total RNA was used for reverse transcription. 
Expression of miR-146a and U6B small nuclear RNA were measured with TaqMan® 
MicroRNA Assays Kit (Life Technologies Ltd, Paisley, UK). U6B was used as 
internal control. QuantiTect SYBR Green PCR kit (Qiagen, Manchester, UK) was 
used to determine the relative levels of two NF-κB target genes vascular cell adhesion 
molecule 1 (VCAM1) and chemokine C-C motif ligand 2 (CCL2). β-actin was used as 
internal control. The primers were 5′-CATTTGACAGGCTGGAGATAGA-3′ and 5′-
CTCTTGGTTTCCAGGGACTT-3′ for VCAM1 (GenBank Accession Number 
M73255.1), 5′-GGCTGAGACTAACCCAGAAAC3′ and 
 9 
5′GAATGAAGGTGGCTGCTATGA-3′ for CCL2 (GenBank Accession Number 
NM_002982.3), and 5′-GGACCTGACTGACTACCTCAT-3′ and 5′-
CGTAGCACAGCTTCTCCTTAAT- 3′ for β-actin (NM_001101.3). The method of 
2-ΔΔCT was used for analysis of the data.7 
 
Immunohistochemistry and in situ hybridization 
     Cryostat sections of lumbar spinal cords from 4% paraformaldehyde-perfused EAE 
mice at day 10 after EAE induction (D10, n = 5), in the initial acute phase paralysis of 
EAE  with a clinical score of 4 (APP, n = 5), and control mice without EAE induction 
(n = 5) underwent immunohistochemical staining for endothelial specific marker with 
rat anti-PECAM-1 monoclonal antibody (1:50, BD Biosciences, Oxford, UK) 
followed with a secondary goat anti-rat IgG Alexa Fluor 555 (1:400, Life 
Technologies Ltd, Paisley, UK) and nuclei staining with Hoechst 33342 (Life 
Technologies Ltd, Paisley, UK). Images were captured using a Leica DMRB 
fluorescence microscope with a Hamamatsu C4742-95 digital camera and HiPic 
software (Herrsching, Germany). Then In situ hybridization of miR-146a was 
performed using double-digoxigenin labelled miRCURY LNA™ probe (Exiqon, 
Vedbaek, Denmark) after proteinase K digestion following the manufacturer’s 
protocol with modification.7 Briefly slides were treated with 2 µg/ml proteinase K 
(Roche West Sussex, UK) at 37 °C for 10 min, fixed for 5 min in 4% 
paraformaldehyde and dehydrated in 70% ethanol. Sections were prehybridised in 
hybridisation buffer consisting of 50% formamide, 5X saline sodium citrate (SSC) 
and 100 µg/ml sheared salmon sperm DNA at 52 °C for 30 min. Double-digoxigenin 
labelled miRCURY LNA™ probe miR-155 oligonucleotide at concentration of 5 nM 
was hybridised with the sections overnight at 52 °C. A similarly labelled LNA 
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scrambled oligonucleotide was used as a negative control. Sections were washed 
through a series of 5 min washes in 5X to 0.2X SSC at 55°C, incubated overnight 
with sheep anti-digoxigenin antibody conjugated with alkaline phosphatase (1:1000, 
Roche West Sussex, UK), then incubated in NBT/BCIP (Roche West Sussex, UK) 
and levamisole (Vector Labs, Peterborough, UK) at 30 °C, then washed in KTBST 
(50 mM Tris HCl pH 7.5, 150 mM NaCl, 20 mM KCl, 0.5% Tween-20) for 1 to 6 h to 
reduce the background signal. Sections were re-stained in Hoechst 33342. NBT/BCIP 
precipitate was photographed using a Nikon Eclipse 80i fluorescence microscope with 
a MBF CX9000 digital camera and PictureFrame software. 
 
Cell transfection 
     30 nM of Pre-miR-146a were transfected into hCMEC/D3 cells using siPORT 
Amine transfection agent (Life Technologies Ltd, Paisley, UK), whereas 60 nM of 
miR-146a inhibitor (Anti-miR-146a) and siGENOME SMARTpool siRNAs for 
human RelA, IRAK1, TRAF6, STAT1, ROCK1, RhoA, and NFAT5 (ThermoFisher 
Scientific, Epsom, UK) were transfected into cells using Lipofectamine 2000 (Life 
Technologies Ltd, Paisley, UK). Non-targeting scrambled Pre-miR, Anti-miR or 
siRNA control pools was used as negative controls respectively. Cy3™ dye-Labeled 
Pre-miR or Anti-miR Negative Control #1 (Life Technologies Ltd, Paisley, UK), 
siGLO Red Transfection Indicator (ThermoFisher Scientific, Epsom, UK) was used 
for analysing transfection efficiency.  
 
Leukocyte adhesion assay under shear flow 
     Jurkat T cell and primary human T cell adhesion assay was performed as 
previously described with modification.17,18 Briefly, hCMEC/D3 cells were grown on 
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collagen-coated ibidi μ-Slide VI0.4 6 channel slides (ibidi GmbH, Martinsried, 
Germany) until confluence. Primary human T cells were activated by 48 h stimulation 
with IL-2 (10 ng/ml) and phytohemagglutinin (1 μg/ml). Then Jurkat T cells or 
activated primary human T cells (2 x 106/ml) were labelled with 5 mM CMFDA (5-
chloromethylfluorescein diacetate, Life Technologies Ltd, Paisley, UK) and were 
allowed to flow through the channel and accumulate for 5 min at low shear stress (0.5 
dyn/cm2). Shear stress (τ) was calculated according to τ = 176.1 ηФ (η = 0.01, Ф = 
volumetric flow rate). Images were recorded at one frame per second with an inverted 
time-lapse fluorescence microscope (Olympus IX70, Tokyo, Japan) by using Image 
Pro Plus software (Media Cybernetics Inc., Bethesda, USA). Then culture medium 
was pulled through the channel at a physiological shear stress (1.5 dyn/cm2) for 1 min 
to wash away leukocytes which were not firmly adhered to endothelium. Under 
physiological shear stress, images were taken randomly from, at least 5 fields per 
channel (640 x 480 μm2/field). Firmly adherent Jurkat T cells were then counted using 
Image Pro Plus software. 
 
Immunocytochemistry 
     hCMEC/D3 cells grown on glass coverslips coated with collagen were fixed with 
4% paraformaldehyde and permeabilized with methanol and acetone at -20oC for 10 
and 1 min respectively, then incubated with rabbit anti-NF-κB p65 (1:100, Cell 
Signaling Technology Inc. Danvers, MA, USA) followed by goat anti-rabbit IgG 
Alexa Fluor 488 (1:400, Life Technologies Ltd, Paisley, UK). Cell nuclei were 
stained using Dapi Fluoromount-G (SouthernBiotech, Birmingham, Alabama, USA). 
Images were captured with a Zeiss Axiophot fluorescent microscope. Number of cells 
with nuclear staining of NF-κB p65 was expressed as percentage of total cell numbers 
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demonstrated by DAPI, for each experiment and each condition performed with 
duplicates, at least 100 cells were counted in 3 – 6 randomly selected fields.    
 
Western blot analysis 
     Cell lysates were separated by 10% (20% for RhoA) SDS-PAGE gels and 
transferred onto nitrocellulose membranes (Amersham, Buckinghamshire, UK), 
probed with rabbit anti-IRAK1 or TRAF6 or RelA or ROCK1 (1:1000, Cell Signaling 
Technology, Danvers, MA, USA), or rabbit anti-NFAT5 (1:1000, Thermo Scientific, 
Northumberland, UK) or STAT1 (1:500, Santa Cruz Biotechnology, Inc., Dallas, 
Texas, USA), or mouse anti-RhoA (1:100, Cytoskeleton, Inc. Denver, CO, USA), or 
mouse anti-VCAM1 (1:100, R&D Systems Europe Ltd, Abingdon, UK), or mouse 
anti-β-actin (1:5000 Sigma, Dorset, UK), followed with horseradish peroxidise-
conjugated goat anti-rabbit IgG (1:3000; Life Technologies Ltd, Paisley, UK) or anti-
mouse IgG (1:3000 for RhoA, 1:14000 for β-actin; Pierce Biotechnology, Cheshire, 
UK). Immunoblots were then developed by enhanced chemiluminescence detection 
(ECL, Amersham, Buckinghamshire, UK).  
 
Lentiviral transduction of 3’ UTR reporter vectors and luciferase assay 
     The luciferase reporter lentiviral vector constructs containing the puromycin 
resistance gene and the luciferase gene from the firefly Photinus pyralis with the 
3’untranslated region (UTR) of RhoA (1061 bases), NFAT5 (5’-2100 bases) (Applied 
Biological Materials Inc., British Columbia, Canada) were used to transduce 
hCMEC/D3 cells with a multiplicity of infection of 3. Mutated 3’ UTR versions of 
putative target genes were obtained by replacing the corresponding miR-146a target 
sites with AAGA using site-directed mutagenesis.  24 h after transduction, cells were 
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transfected with Pre-miR-146a or scrambled Pre-miR. 72 h later, luciferase activity 
was quantified using the Steady-Glo® Luciferase assay system (Promega, Madison, 
WI, USA) and luminescence was determined using the FLUOstar OPTIMA plate 
reader (BMG LABTECH GmbH, Ortenberg, Germany). 
 
Statistical analysis 
     All values are presented as means ± SEM. Student paired t test was used for 
human MS samples, Jurkat T cell or primary human T cell adhesion assay. Student t 
test was used for 3’ UTR luciferase assay. For other experiments, one-way ANOVA 
(analysis of variance) was used for single time point experiments and posthoc with 
Bonferroni correction for multiple comparisons on SPSS software. Two-way ANOVA 
was used for multiple time point experiments. Statistical significance was considered 
if P < 0.05. 
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Results 
Neuroinflammation induces up-regulation of CNS endothelial miR-146a 
To elucidate the role of endothelial miR-146a in BBB dysfunction in 
neuroinflammatory diseases such as MS, we first characterized its expression in 
human brain microvessels of MS lesions, isolated by laser capture microdissection. In 
comparison to normal appearing white matter, cerebral microvascular miR-146a 
increased approximately 1.5 fold in the active lesions of MS (Figure 1A). We then 
examined the temporal expression pattern of miR-146a in the spinal cord 
microvasculature of EAE mice, isolated by enzyme digestion. The enrichment of 
endothelium was confirmed, as previously reported by our lab,7 by high gene 
expression levels of endothelial specific markers (claudin-5, PECAM-1) and by low 
expression of astrocyte marker GFAP and leukocyte marker CD45, compared to the 
reference gene β-actin. Mice at initial acute-phase paralysis of EAE (EAE-APP) with 
a clinical score of 4 showed an 8-fold increase of miR-146a in the microvessels of the 
spinal cord compared to normal control animals (Figure 1B). The level of miR-146a 
returned back to basal levels during EAE-remission stage. We further demonstrated, 
via in situ hybridization, the abundant expression of miR-146a in the lumbar spinal 
cord of EAE-APP mice, and its co-localization with the endothelial maker PECAM-1 
(Figure 1C). In non-EAE control mice or in EAE mice at day10 (D10) after 
immunization (prior to onset of signs), endothelial expression of miR-146a was not 
detectable or very low, respectively (Figure 1C). In cultured human brain endothelial 
hCMEC/D3 cells, an in vitro BBB model, tumor necrosis factor alpha (TNFα) and 
interferon gamma (IFNγ) (1 ng/ml each) up-regulated the expression of miR-146a at 6 
and 24 h by 4 fold of that in non-stimulated control cells and this increase was still 
largely maintained (~3 fold) by 48 h post-cytokine stimulus (Figure 1D). These 
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results indicate that inflammatory mediators induce a tightly spatial and temporal 
expression of miR-146a, thereby suggesting an important role at brain endothelium in 
affected areas during neuroinflammation. 
 
 
Brain endothelial miR-146a partially prevents cytokine-stimulated leukocyte 
adhesion 
As miR-146a levels increase in brain endothelium during neuroinflammation, we then 
further investigated the role of brain endothelial miR-146a in BBB dysfunction, 
particularly on leukocyte adhesion to brain endothelium in vitro. We firstly 
manipulated the levels of miR-146a in hCMEC/D3 cells grown on 6-channel slides by 
transfection with Pre-miR-146a or Anti-miR-146a to increase or decrease the 
expression of miR-146a respectively (Supplementary Figures 1A and B). For all 
experiments, over 90% transfection efficiency was consistently achieved 
(Supplementary Figure 1C). At day 1 post-transfection, cells were treated with 1 
ng/ml TNFα and IFNγ for 24 h and exposed to CMFDA-labelled Jurkat T cells for 5 
min at 0.5 dyn/cm2 to mimic the blood flow in the microvasculature (Supplementary 
Videos A-C). Jurkat T cells adhered to endothelial cells were analysed after flushing 
away non-adhered cells at 1.5 dyn/cm2. We observed that ectopic expression of miR-
146a or inhibition of basal miR-146a by Anti-miR-146a did not affect Jurkat T cell 
adhesion to non-stimulated hCMEC/D3 monolayers (Figures 2A and B). In contrast, 
stimulation of endothelium with 1 ng/ml TNFα and IFNγ for 24 h induced increase in 
Jurkat T cell adhesion by around 10 fold, under flow condition, when compared to 
non-treated cells (Figures 2A and B). Furthermore, over-expression of miR-146a in 
brain endothelium partially prevented Jurkat T cell adhesion to cytokine-activated 
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hCMEC/D3 cells by ~21% (Figure 2A; Supplementary Videos B and C). Preventing 
cytokine-induced increase in miR-146a resulted in augmented Jurkat T cell adhesion 
by ~39% (Figure 2B). Similarly, over-expression of miR-146a in brain endothelium 
partially prevented primary human T cell adhesion to cytokine-activated hCMEC/D3 
cells by ~17% (Figures 2C). Altogether, these results indicate TNFα and IFNγ induce 
increase of brain endothelial miR-146a that negatively modulates Jurkat T cell 
adhesion.    
 
miR-146a modulates brain endothelial NF-κB activation 
The critical role of NF-κB in leukocyte adhesion to and migration across endothelium 
is well established, so we next wanted to investigate whether miR-146a modulates 
NF- κB activity in brain endothelium.  Following immunostaining of NF-κB p65, our 
results show that 1 ng/ml of TNFα and IFNγ induced nuclear translocation of NF-κB 
p65 in hCMEC/D3 cells which peaked at 0.5 h and was largely sustained from 6 to 24 
h (Figure 3A-C).  Over-expression of miR-146a decreased cytokine-induced NF-κB 
p65 nuclear translocation at all three time points, by 8%, 20% and 10% at 0.5, 6 and 
24 h, respectively, compared to their scrambled controls (Figure 3A and B). By 
contrast, miR-146a knock-down enhanced cytokine-induced NF-κB p65 nuclear 
translocation by 3%, 7% and 15% over that of scrambled control at 0.5, 6 and 24 h, 
respectively (Figure 3C). In line with a previous report on the role of NF-κB on 
monocyte adhesion to umbilical vein endothelium,18 we confirmed that knock-down 
of RelA (NF-κB p65) via small interference RNA (Figure 3D) decreased Jurkat T cell 
adhesion to cytokine-activated brain endothelium by 67% in comparison with its 
scrambled control (Figure. 3E). These results suggest that cytokine-induced miR-146a 
 17 
up-regulation in brain endothelium negatively regulated upstream activators of NF-κB 
signaling. 
 
miR-146a targets IRAK1 and TRAF6 in brain endothelium 
As microRNAs regulate cellular processes and cell signaling through silencing target 
molecules, using different online databases (microRNA.org, MiRanda and 
TargetScan), we identified 4 potential target genes for miR-146a with known NF-κB 
regulatory activity, STAT1, ROCK1, RhoA and NFAT5, in addition to the well-
known miR-146a targets, IRAK1 and TRAF6. Indeed, these two genes have already 
been validated as targets of miR-146a in several cell types including monocytes, T 
cells and astrocytes,10,12,13 and are involved in the regulation of NF-κB activity and 
expression of NF-κB target genes such as VCAM1 and TNFα.13,14 We transfected 
hCMEC/D3 cells with Pre-miR-146a or scrambled control, then treated cells with 1 
ng/ml TNFα and IFNγ for 0.5, 6 and 24 h. In the control conditions, cytokines 
increased IRAK1 (by 1.25 fold over untreated control) at 0.5 h, with levels decreasing 
considerably (by 25 ~ 40%) at later time points (Figures 4A and B). In contrast, 
TRAF6 expression levels were increased at all three time points by cytokine treatment 
(1.1 – 1.4 fold of untreated control) (Figures 4A and C). We show that ectopic 
expression of miR-146a suppressed levels of IRAK1 and TRAF6 (Figures 4A-C), in 
either untreated or cytokine-treated hCMEC/D3 cells at all three time points by 
Western blot analysis. Moreover, knock-down of the expression of IRAK1 or TRAF6, 
alone or in combination, via small interference RNAs (siIRAK1, siTRAF6) 
(Supplementary Figures 3A and B), significantly decreased cytokine-induced 
leukocyte adhesion (Figures 4D-F) and this effect was associated with decreased 
nuclear translocation of NF-κB (Figure 4G). We did not observe synergistic or 
 18 
additive effects when knock-down of TRAF6 and IRAK1 was conducted 
simultaneously by small interference RNAs.  
Two additional potential miR-146a targets, STAT1 and ROCK1, have been 
respectively validated in prostate carcinoma cells19 and Treg cells.20 However, in brain 
endothelium, miR-146a suppressed neither STAT1 nor ROCK1 protein expression 
(Supplementary Figure 2).  
 
miR-146a targets NFAT5 and RhoA in brain endothelium 
We further investigated two novel potential targets for miR-146a in brain endothelium 
that have not previously been validated: RhoA and NFAT5. We transfected 
hCMEC/D3 cells with Pre-miR-146a, then treated them with 1 ng/ml TNFα and IFNγ 
for 0.5, 6 and 24 h. In controls, cytokines increased NFAT5 (around 20% more than 
untreated control) from 0.5 to 6 h, after which levels decreased slightly (Figures 5A 
and B). In contrast, RhoA levels decreased by 20% at 6 h, then increased by 20% at 
24 h (Figures 5A and C). We show that ectopic expression of miR-146a suppressed 
levels of both NFAT5 and RhoA (Figures 5A-C), in either untreated or cytokine-
treated hCMEC/D3 cells at all three time points by Western blot analysis. Moreover, 
knock-down of NFAT5 or RhoA expression using small interference RNAs 
(siNFAT5, siRhoA) (Supplementary Figure 3C), significantly decreased leukocyte 
adhesion to cytokine-activated brain endothelium by 33% or 37% respectively 
(Figures 5D and E). siNFAT5 down-regulated nuclear translocation of NF-κB by15%, 
14% and 11% at 0.5, 6 and 24 h, respectively, compared to their scrambled controls, 
while siRhoA decreased nuclear translocation of NF-κB by 7% at all three time points 
(Figure 5F). Furthermore, in hCMEC/D3 cells transduced with lentiviral luciferase 
reporter vectors containing the 3’ UTR of RhoA or NFAT5, over-expression of miR-
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146a significantly decreased luciferase activity by 50% and 30% respectively in 
comparison with scrambled controls, but no decrease was detected in cells transduced 
with lentiviral luciferase reporter vector containing mutated 3’ UTR versions of either 
RhoA or NFAT5 (Figure 5G). These results demonstrated that miR-146a play a key 
role in modulating NF-κB activity by repressing multiple cytokine-effectors. 
 
miR-146a inhibits expression of NF-κB-target genes in brain endothelium 
As miR-146a modulates NF-κB activation by repressing multiple targets, we then 
examined its effect on the mRNA and protein expression of two NF-κB-target genes: 
VCAM1 and CCL2, which are key players in leukocyte adhesion to endothelium. In 
cytokine-treated hCMEC/D3 cells, VCAM1 and CCL2 mRNA levels increased by 70- 
and 50-fold over that of untreated cells, respectively, whereas over-expression of 
miR-146a by transfection with Pre-miR-146a decreased the cytokine-induced levels 
of VCAM1 and CCL2 by 50% (Figure 6A). In contrast, decreased expression of miR-
146a by transfection with Anti-miR-146a increased the level of VCAM1 mRNA in 
cytokine-activated hCMEC/D3 cells (Figure 6B). CCL2 mRNA levels were also 
increased by transfection with Anti-miR-146a but did not reach statistical significance. 
Consistently, knock-down of NFAT5 and RhoA by siRNA decreased the transcription 
levels of VCAM1 and CCL2 by 50% in cytokine-stimulated cells (Figure 6D), 
whereas siIRAK1 and siTRAF6 did not markedly alter the levels of VCAM1 and 
CCL2 mRNA (Figure 6C). We further examined the protein levels of VCAM1 in 
hCMEC/D3 cells transfected with Pre-miR-146a or with siRNA for its target 
molecules. Cytokines increased the level of VCAM1 protein, whereas ectopic 
expression of miR-146a significantly decreased cytokine-induced levels of VCAM1 
protein (Figure 6E). In addition, siRNA-mediated knock-down of IRAK1, TRAF6, 
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RhoA and NFAT5 significantly decreased VCAM1 protein levels in cytokine-
activated cells (Figures 6F-H), which is in line with that down-regulated by siRelA 
(Figure 6I). 
 
Taken together, these results indicate that cytokine-induced increase in brain 
endothelial miR-146a negatively regulates NF-kB activation via repression of 
multiple targets upstream of NF-kB signaling, highlighting its anti-inflammatory role 
in brain endothelium. 
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Discussion 
miR-146a has been demonstrated as a NF-kB inhibitor in several cell types other than 
brain endothelium. In this study we provide evidence that brain endothelial miR-146a 
represses multiple targets: NFAT 5, RhoA, IRAK1 and TRAF6, to inhibit NF-kB 
activity, and subsequently negatively modulate leukocyte adhesion (Figure 7).  
 
In vivo, we have shown that miR-146a is significantly up-regulated in isolated 
microvessles of MS active lesion and of spinal cords of mice during EAE-APP. In the 
spinal cords of EAE mice, we further confirmed the expression of miR-146a in 
endothelium by in situ hybridization combined with immunohistochemistry. The 
expression of miR-146a starts to appear prior to the onset of signs, reaches high levels 
during EAE-APP when pro-inflammatory cytokines are extensively produced,1-3 and 
maximum cell infiltration is occurring around the vasculature, and draws back to 
baseline at remission when BBB dysfunction is restored and with minimal cell 
infiltration.7 This observation is in line with the increased expression of miR-146a 
detected in active MS lesion and in cytokine-treated astrocytes.21 We also demonstrate 
that miR-146a is up-regulated in cytokine-activated cultured BECs, where NF-κB 
activation occurs earlier than miR-146a up-regulation. It is possible that miR-146a is 
transcribed upon onset of inflammation by NF-κB and levels increase during acute 
stage of inflammatory conditions in order to resolve neuroinflammation (Figure 7). It 
is thus reasonable to predict that miR-146a may act as an anti-inflammatory 
microRNA in astrocytes and brain endothelial cells as they form a functional 
neurovascular unit to maintain the integrity of BBB.22 
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NF-κB has been shown to be a central player in several autoimmune diseases such as 
MS.3 The NF-κB pathway fulfils diverse roles in development, maturation, activation 
and proliferation of lymphocytes, and in regulating pro-inflammatory and anti-
inflammatory function of dendritic cells and macrophages.3 Brain endothelial 
transcripts regulated by NF-κB may include not only miR-146a11 but also nitric oxide 
synthases, pro-inflammatory cytokines, chemokines and cell adhesion molecules.3 In 
cultured brain,23 umbilical vein18 or retina24 endothelial cells, inhibition of NF-κB 
activity reduces TNFα-induced permeability and/or leucocyte migration. In vivo, 
reagents used to block NF-κB activity can reduce the incidence of disease and clinical 
score of EAE.25 Here we show that endothelial miR-146a diminishes both Jurkat T 
cell and primary T cell adhesion to BECs, an effect that is associated with a decrease 
in NF-kB nuclear translocation. Similar effects on leukocyte adhesion to endothelium 
have been observed with NF-kB inhibitors such as MG-132, adenoviral IκB,18,23 and 
small interference for RelA (Figure 3D). The effect of miR-146a on NF-kB nuclear 
translocation was relatively small at the very early time point. This may result from 
the fine tuning properties of miRNAs7 and also the characteristic of NF-kB nuclear 
translocation that peaks at early time points and then resolves gradually (Figure 3A). 
Furthermore the relative large effect of miR-146a at later time points may result from 
additive effects of NF-kB induced negative feedback regulators such as Bcl3 and 
IκB.3 Nevertheless, the general effect of endothelial miR-146a on leukocyte adhesion 
to BECs through inactivating NF-κB is evident. Even though MS is regarded as a T 
lymphocyte-dependent chronic inflammatory disease, other cells like B cells, 
dendritic cells, macrophages and CNS resident glia also contribute to the pathogenesis 
of disease.3 The effects of endothelial expression of miR-146a on other cell types 
including various subsets of T cells remain to be explored. 
 23 
 It has been demonstrated that miR-146a negatively modulates NF-κB through down-
regulating TRAF6 and IRAK1.10-13 In BECs, we also demonstrated that miR-146a 
repressed translation of TRAF6 and IRAK1 in response to TNFα and IFNγ. Knock-
down of TRAF6 and IRAK1 either individually or simultaneously show similar 
effects as miR-146a on Jurkat T cell adhesion and nuclear translocation of NF-κB, 
although simultaneous knock-down of both proteins together did not result in 
synergistic effects. TRAF6 and IRAK1 have been mainly associated with IL-1β signal 
transduction leading to NF-κB activation,10-13 but several reports demonstrate a role 
for these two signalling molecules in TNFα-induced NF-κB activation.26-28 In addition, 
an endogenous IL-1 inhibitor, IL1 receptor antagonist (IL-1RA), blocked IL-1β- but 
not TNFα/INFγ-induced NF-kB activation and Jurkat T cell adhesion to BECs 
(Supplementary Figure 4), indicating that TNFα-induced IL-1 expression was not 
involved in the miR-146a-mediated TRAF6 and/or IRAK1 inhibition on NF-κB 
activity. This effect is however limited, suggesting the involvement of other NF-kB 
modulators targeted by miR-146a that are specific for TNFα and IFNγ. However, 
levels of another two known miR-146a targets, ROCK1 (ref. 19) and STAT1 (ref. 20), 
were not affected by miR-146a over-expression, suggesting tissue-specific actions of 
miRNAs.  
 
We also identified another two novel miR-146a targets known to modulate NF-kB 
activity, NFAT5 and RhoA. NFAT5 together with NFAT1 – 4 belong to the Rel 
family, sharing 15 – 17% identity with p50 in the Rel homology region.29 Most 
reports on NFAT5 refer to its transcriptional activity in the context of hypertonicity.29 
However its role in inflammation is only beginning to emerge, with evidence that pro-
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inflammatory cytokines TNFα, IL-1, IL-6, IL-18, and chemokines such as CXCL8, 
CCL2 and CCL5 are transcriptional targets of NFAT5 in various cell types and under 
various inflammatory stimuli.29,30 Furthermore there appears to be cross-talk between 
NFAT5 and NF-κB30 or Wnt/β-catenin31, where the latter is important for BBB 
development. Accumulating evidence suggests the onset of local or systemic 
hyperosmolality during the course of various inflammatory disorders such as diabetic 
microvascular lesions and inflammatory bowel disease. Recently it has been reported 
that a high salt diet leads to a more severe EAE clinical outcome through an effect 
relying on p38-MAPK and NFAT5-dependent Th17 development.32 We provide 
further evidence that NFAT5 is involved in the activation of cerebral endothelium by 
cytokines, particularly concerning regulation of NF-κB activation and T cell adhesion. 
 
RhoA, Cdc42 and Rac1 are members of the Rho family of small GTPases. 
Endothelial Rho has been shown to play a crucial role in leukocyte migration across 
of BECs either by modulating the cytoskeleton to embrace leukocyte by promoting 
docking structures33 or by acting as an intercellular adhesion molecule-1 signal 
transducer.34 In other endothelium (mostly HUVECs), RhoA has been shown to 
modulate expression of cytokines, adhesion molecules and chemokines via 
Rho/ROCK/(actin cytoskeleton)/NF-kB signaling cascade.4 Rho family members and 
their exchange factors Dbl, Ost, and Vav potently activate NF-kB, though other 
transcription factors such as the activating protein-1 (AP-1) family member c-Jun may 
also coordinately act together to modulate NF-kB activities. Our results demonstrating 
a link between miR-146a and RhoA are in agreement with the role of RhoA in NF-kB 
activation and leukocyte adhesion to endothelium. 
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We have also examined the levels of adhesion molecules down-regulated by miR-
146a (Figure 6), because of the well-documented observation that NF-κB initiates 
adhesion molecule expression and chemokine production in multiple cell types 
including brain endothelial cells.3 It seems a reasonable assumption therefore, that 
cerebral endothelial miR-146a may regulate signal transducers for NF-κB activation 
posttranscriptionally, thereby leading to decreased expression of NF-κB 
transcriptional targets. Indeed, our results are in line with those obtained in HUVECs, 
where manipulating levels of miR-146 had a significant indirect effects on 
transcription of intercellular adhesion molecule-1 (ICAM1), VCAM1, E-selectin, 
CCL2, whereas these effects are not only due to targeting of NF-κB activation but 
also other signaling molecules such as mitogen-activated protein kinase/early growth 
response pathway and AP-1 signaling.15 Unexpectedly, we also observed that 
siIRAK1 and/or siTRAF6 decreased VCAM1 protein levels without affecting its 
corresponding mRNA levels. It is possible that the role of these two signalling 
proteins in the inflammatory activation of brain endothelial cells induced by cytokines 
is a complex process and that, in addition to their role in NF-kB-mediated 
transcriptional activation, IRAK1 and TRAF6 may regulate inflammatory molecules 
such as VCAM1 at the post-translational level. As an example, IL-1 activates a 
translational control mechanism that modulates expression of a group of genes, 
including IL-6, via IRAK135. Alternatively, combination of pro-inflammatory 
cytokines increases the half-life of VCAM1 mRNA36, and TRAF6 and IRAK1 
actively regulate the ubiquitin-proteasome system.37 It is thus conceivable that 
VCAM1 protein turnover is affected by ablation of IRAK1 and/or TRAF6 in the 
absence of apparent changes of VCAM1 mRNA levels by a mechanism that remains 
to be determined. 
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 In summary, we have delineated further the underlying mechanisms through which 
miR-146a affects T cell adhesion to human brain endothelium by identifying two 
novel targets NFAT5 and RhoA, and we have demonstrated the role of IRAK1 and 
TRAF6, two signalling molecules usually associated with IL-1R and Toll like 
receptor responses, in brain endothelial activation by TNFα and IFNγ, we have 
characterized the temporal and spatial expression of miR146a in CNS endothelium in 
MS active lesions, EAE model and cultured brain endothelium. Since the complex 
signaling networks appear to control inflammation progression,28,38  it is unlikely that 
rational therapeutic strategies should focus on modulating the activity of one signaling 
molecule. Indeed the emerging role of miRNAs in directly regulating complex 
signaling networks involved in inflammation such as cell adhesion molecules39,40 by 
targeting the expression of several genes makes them suitable therapeutic targets for 
neuroinflammatory disorders. The limited increase of miR-146a in MS brain 
endothelium further stresses the necessity to increase miR-146a through therapeutic 
manipulation to counteract inflammatory responses, thereby potentially preventing the 
progression of MS pathogenesis. 
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Figure Legends         
Figure 1. miR-146a is increased in CNS microvessels and cultured brain endothelium 
during inflammation. (A) Quantitative RT-PCR analysis of miR-146a in brain 
endothelial cells isolated by laser capture microdissection from normal appearing 
whiter matter (NAWM) and MS active lesions (n = 6). Data show the relative 
abundance of miR-146a normalized to the small nuclear RNA U6B. P = 0.039 by 
paired Student’s t test. (B) Expression of miR-146a in mouse spinal cord microvessels 
isolated by enzyme digestion was analysed using quantitative RT-PCR. Samples of 3 
mice were pooled as one, 9 mice were used for each group. Normal, control Biozzi ABH 
mice; APP, EAE mice at acute-phase paralysis with a clinical grade score of 4 at day 
17; Remission, EAE mice at the first remission stage showing a clinical score of  0.5 
and gain of body weight at day 28. Data represent mean ± s.e. n = 3. ***P < 0.001 
compared with Normal or Remission via ANOVA. (C) Representative 
photomicrographs show by in situ hybridization in combination of 
immunohistochemistry the expression of miR-146 in PECAM-1 positive spinal cord 
microvessels of a mouse at day 10 after EAE induction (D10, upper panels) or an 
EAE-APP mice at day 17 (lower panels) respectively. Left panels show expression of 
miR-146a (red arrows). Middle panels show immunostaining of endothelium-specific 
marker PECAM-1 (white arrows). Right panels show merged images to demonstrate 
colocalization of miR-146a and PECAM-1 (red arrows). Hoechst 33342 labels nuclei 
(light blue). Scale bar, 25 μm. (D) Brain endothelial cell line hCMEC/D3 cells were 
confluent and left unstimulated or stimulated with 1 ng/ml of TNFα and IFNγ for 0.5, 
6, 24, or 48 h. Expression of miR-146a was analyzed with quantitative RT-RCR and 
normalized to the small nuclear RNA U6B. Values of non-stimulated cells were set as 
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1. Data represent mean ± s.e. n = 3. *P < 0.05, **P < 0.01 compared with untreated 
control via ANOVA. 
 
 Figure 2. miR146a modulates Jurkat T cell adhesion to cytokine-stimulated 
hCMEC/D3 cells. hCMEC/D3 cells in 6-channel slides were transfected with Pre-
miR-146a or scrambled Pre-miR, and left untreated or treated with 1 ng/ml TNFα and 
IFNγ for 24 h. hCMEC/D3 cells were then exposed to CMFDA-labelled Jurkat T cells 
for 5 min at 0.5 dyn/cm2. (A) Quantitative analysis of effects of Pre-miR-146a on 
Jurkat T cell adhesion. (B) Quantitative analysis of effects of Anti-miR-146a on 
Jurkat T cell adhesion. (C) Quantitative analysis of effects of Pre-miR-146a on 
primary human T cell adhesion. Data represent mean ± s.e. n = 4 for Jurkat T cell 
adhesion assay, n = 3 for primary human T cell adhesion assay, experiments for each 
group at each condition were performed in duplicates. *P < 0.05, **P < 0.01, ***P < 
0.001 via Student paired t test.  
 
Figure 3. miR-146a in hCMEC/D3 cells negatively modulates nuclear NF-κB 
translocation. (A) Photomicrographs show NF-κB p65 (RelA) staining in scrambled 
or Pre-miR-146a transfected hCMEC/D3 cells untreated or treated with 1 ng/ml TNFα 
and IFNγ for 0.5, 6 and 24 h. Scale bar, 100 μm. (B) Effects of Pre-miR-146a on 
nuclear translocation of NF-κB p65 in hCMEC/D3 cells. Note ectopic expression of 
miR-146a suppressed nuclear translocation of NF-κB p65 at all three time points. 
Two-way ANOVA tests of all the time points after cytokine treatment demonstrate 
significant difference between the Scrambled and Pre-miR-146a groups (P < 0.001). 
One-way ANOVA was used to compare the difference at each time point between the 
two groups. Data represent mean ± s.e. n = 3, *P < 0.05, **P < 0.01. (C) Effects of 
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Anti-miR-146a on nuclear translocation of NF-κB p65 in hCMEC/D3 cells. Note that 
knock-down of miR-146a increased nuclear translocation of NF-κB p65 at all three 
time points. Two-way ANOVA tests of all the time points after cytokine treatment 
demonstrate significant difference between the Scrambled and Anti-miR-146a groups 
(P < 0.001). One-way ANOVA was used to compare the difference at each time point 
between the two groups. Data represent mean ± s.e. n = 3, *P < 0.05. (D) RelA small 
interference (siRelA) or small interference control (siControl) was transfected into 
hCMEC/D3 cells in 12-well plates, 48 h later, cells were left untreated or treated with 
1 ng/ml TNFα and IFNγ for 0.5, 6 and 24 h, subject to Western blot for RelA. Note 
that siRelA suppressed expression of RelA in either untreated or cytokine-stimulated 
cells at all three time points. siRNA -, siControl; siRNA +, siRelA. (E) Decreased 
expression of RelA prevented Jurkat T cell adhesion to cytokine-stimulated 
hCMEC/D3 cells. Data represent mean ± s.e. n = 4, *P < 0.05, **P < 0.01 via Student 
paired t test. 
 
Figure 4. miR-146a targets IRAK1 and TRAF6 to modulate NF-κB activation and 
Jurkat T cell adhesion. (A) Western blot analysis show that over-expression of miR-
146a via transfection with Pre-miR-146a repressed the expression of IRAK1 and 
TRAF6 in hCMEC/D3 cells either unstimulated or cytokine (1 ng/ml TNFα/IFNγ)- 
stimulated for 0.5, 6 and 24 h. (B, C) Quantification of protein levels of IRAK1 and 
TRAF6 via ImageJ. Data represent mean ± s.e. n = 3, *P < 0.05, **P < 0.01, ***P < 
0.001 via ANOVA with posthoc comparison and Bonferroni correction. (D) Knock-
down the expression of IRAK1 via small interference RNA for IRAK1 (siIRAK1) 
decreased Jurkat T cell adhesion to cytokine-stimulated hCMEC/D3 cells. (E) Knock-
down the expression of TRAF6 via siTRAF6 down-regulated Jurkat T cell adhesion 
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to cytokine-stimulated hCMEC/D3 cells. (F) Knock-down the expression of IRAK1 
and TRAF6 simultaneously decreased Jurkat T cell adhesion to cytokine-stimulated 
hCMEC/D3 cells. Data represent mean ± s.e. n = 3 - 4, *P < 0.05, **P < 0.05, ***P < 
0.001 via ANOVA. (G) Statistical analysis the effects of siIRAK1 and siTRAF6 on 
nuclear translocation of NF-κB. Two-way ANOVA tests of all the time points after 
cytokine treatment demonstrate significant difference between the siControl and 
siIRAK1 or siTRAF6 or siIRAK1 + siTRAF6 groups (P < 0.01). One-way ANOVA 
was used to compare the difference with siControl at each time point. Data represent 
mean ± s.e. n = 3, *P < 0.05, **P < 0.01. 
 
Figure 5. miR-146a targets NFAT5 and RhoA to modulate NF-κB activation and 
Jurkat T cell adhesion. (A) Western blot analysis show that over-expression of miR-
146a via transfection with Pre-miR-146a repressed  the expression of NFAT5 and 
RhoA in hCMEC/D3 cells either untreated or treated with cytokines for 0.5, 6 and 24 
h. (B, C) Quantification of protein levels of NFAT5 and RhoA via ImageJ. Data 
represent mean ± s.e. n = 3, *P < 0.05, **P < 0.01, ***P < 0.001 via ANOVA with 
posthoc comparison and Bonferroni correction. (D) siNFAT5 decreased Jurkat T cell 
adhesion to cytokine-stimulated hCMEC/D3 cells. (E) siRhoA down-regulated Jurkat 
T cell adhesion to cytokine-stimulated hCMEC/D3 cells. Data represent mean ± s.e. n 
= 3 - 4, *P < 0.05, **P < 0.01, ***P < 0.001 via Student paired t test. (F) Statistical 
analysis the effects of siNFAT5 and siRhoA on nuclear translocation of NF-κB. Two-
way ANOVA tests of all the time points after cytokine treatment demonstrate 
significant difference between the siControl and siNFAT5 or siRhoA groups 
(p<0.001). One-way ANOVA was used to compare the difference with siControl at 
each time point. Data represent mean ± s.e. n = 3, **P < 0.01, ***P < 0.001. (G) 3’ 
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UTR luciferase assay demonstrated that miR-146a over-expression led to decreased 
luciferase activity in hCMEC/D3 cells transduced with lentiviral luciferase vector 
containing the 3’ UTR of RhoA or NFAT5 but no with the corresponding mutated 3’ 
UTR versions. Text box demonstrates a sequence alignment of human miR-146a (hsa-
miR-146a) and two target sites in the 3’-UTR of RhoA and one target site in the 3’ 
UTR of NFAT5. Mutated 3’-UTR for RhoA or NFAT5 (mut-RhoA, mut-NFAT5) 
was performed by replacing the corresponding miR-146a target sites with 4 
nucleotides: AAGA. Data represent mean ± s.e. n = 3, *P < 0.05 via Student t test. 
 
Figure 6. miR-146a modulated expression of NF-κB-target genes. (A) hCMEC/D3 
cells were transfected with Pre-miR-146a or scrambled Pre-miR, and left untreated or 
treated with 1 ng/ml TNFα and IFNγ for 24 h. Expression of two NF-κB-target genes 
VCAM1 and CCL2 was analysed by SYBR green quantitative RT-PCR and 
normalized to β-actin, expressed as relative level to scrambled control. (B) 
hCMEC/D3 cells were transfected with Anti-miR-146a or scrambled Anti-miR, and 
left untreated or treated with 1 ng/ml TNFα and IFNγ for 24 h. Expression of VCAM1 
and CCL2 was analysed by SYBR green quantitative RT-PCR and normalized to β-
actin, expressed as relative level to scrambled control. (C) hCMEC/D3 cells were 
transfected with siIRAK1, siTRAF6 or both or with scrambled siControl, and left 
untreated or treated with 1 ng/ml TNFα and IFNγ for 24 h. Expression of VCAM1 and 
CCL2 was analysed by SYBR green quantitative RT-PCR and normalized to β-actin 
and expressed as relative levels to siControl. (D) hCMEC/D3 cells were transfected 
with siRelA, siNFAT5 or siRhoA or scrambled siControl, and left untreated or treated 
with 1 ng/ml TNFα and IFNγ for 24 h. Expression of VCAM1 and CCL2 was analysed 
by SYBR green quantitative RT-PCR and normalized to β-actin and expressed as 
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relative levels to siControl. (E-I) Western blot analysis of the levels of VCAM1 
protein in hCMEC/D3 cells transfection with Pre-miR-146a (E), siIRAK1 or 
siTRAF6 (F), siIRAK1 and siTRAF6 together (G), siRhoA or siNFAT5 (H), siRelA 
(I), which were left either untreated or treated with 1 ng/ml TNFα/INFγ for 24 h. Data 
represent mean ± s.e. n = 3, *P < 0.05, **P < 0.01, ***P < 0.001 via ANOVA.  
 
Figure 7. Mechanisms of miR-146a inhibiting NF-κB and T cell adhesion. Pro-
inflammatory cytokines TNFα and IFNγ act through their specific receptors on brain 
endothelial cells, and activate receptor-associated molecules IRAK1 and TRAF6, 
which then initiate IKKβ- mediated phosphorylation and ubiquitination of IκB, 
leading to the activation and nuclear translocation of NF-κB (p50/p65). NF-κB 
initiates transcription of mRNAs including those for CCL2 and VCAM1. CCL2 acts 
as chemoattractant for T cells, which are attracted and adhere to the brain endothelium 
through interacting with VCAM1. NF-κB also initiates negative feedback modulators 
including primary miR-146a. Primary miR-146a is processed by nuclear RNase III 
enzyme Drosha into Pre-miR-146. Pre-miR-146a is transported to the cytoplasm 
where it is further processed by cytoplasmic RNase III enzyme Dicer into mature 
miR-146a. Both NFAT5 and RhoA positively regulate NF-κB activities. Thus miR-
146a inhibits NF-κB activation through repressing IRAK1, TRAF6, NFAT5 and 
RhoA, leading to decreased expression of CCL2 and VCAM1, which results in 
decreased T cell adhesion to brain endothelium. 
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